Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|The Lancet|2019Cited by 722
Myelin-oligodendrocyte glycoprotein antibody-associated diseaseRomain Marignier, Bernhard Hemmer, Yael Hacohen et al.|The Lancet Neurology|2021Cited by 518
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence WorldwideJyh Yung Hor, Kazuo Fujihara, Nasrin Asgari et al.|Frontiers in Neurology|2020Cited by 399
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalbán, Heinz Wiendl, Christine Lebrun‐Frénay et al.|The Lancet Neurology|2025Cited by 314
Worldwide Incidence and Prevalence of Neuromyelitis OpticaViktoria Papp, Zsolt Illés, Melinda Magyari et al.|Neurology|2020Cited by 303